Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 7, 2008, Pages 909-922

  Galetin, Aleksandra ^a   Gertz, Michael ^a   Houston, J Brian ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

CYP3A4; Drug drug interactions; Intestinal first pass

Indexed keywords

ALFENTANIL; ALPRAZOLAM; ATORVASTATIN; BUSPIRONE; CYCLOSPORIN; CYTOCHROME P450; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DIGOXIN; DRUG METABOLIZING ENZYME; FELODIPINE; FEXOFENADINE; KETOCONAZOLE; MARAVIROC; METHADONE; MIDAZOLAM; NIFEDIPINE; NISOLDIPINE; QUINIDINE; RIFABUTIN; SAQUINAVIR; SILDENAFIL; SIMVASTATIN; TACROLIMUS; TRAZODONE; TRIAZOLAM; UNINDEXED DRUG; VERAPAMIL; ZOLPIDEM;

AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME SUBSTRATE; FIRST PASS EFFECT; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HUMAN; LIVER CIRRHOSIS; PREDICTION; REVIEW;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FOOD-DRUG INTERACTIONS; HUMANS; INTESTINES; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 49649116162     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.7.909     Document Type: Review

References (128)

1. Lown KS, Kolars JC, Thummel KE, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994;22:947-55
2. Madani S, Paine MF, Lewis L, et al. Comparison of CYP2D6 content and metoprolol oxidation between microsomes isolated from human livers and small intestines. Pharm Res 1999;16:1199-205
3. Matsumoto S, Hirama T, Matsubara T, et al. Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab Dispos 2002;30:1240-5
4. Paine MF, Schmiedlin-Ren P, Watkins PB, Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole. Drug Metab Dispos 1999;27:360-4
5. Zhang QY, Dunbar D, Ostrowska A, et al. Characterization of human small intestinal cytochromes P450. Drug Metab Dispos 1999;27:804-9
6. Glaeser H, Drescher S, van der Kuip H, et al. Shed human enterocytes as a tool for the study of expression and function of intestinal drug-metabolizing enzymes and transporters. Clin Pharmacol Ther 2002;71:131-40
7. Lin JH, Chiba M, Baillie TA, Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 1999;51:135-58
8. Paine MF, Hart HL, Ludington SS, et al. The human intestinal cytochrome P450 "pie". Drug Metab Dispos 2006;34:880-6
9. Paine MF, Khalighi M, Fisher JM, et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 1997;283:1552-62
10. von Richter O, Burk O, Fromm MF, et al. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens. Clin Pharmacol Ther 2004;75:172-83
11. Yang J, Tucker GT, Rostami-Hodjegan A. Cytochrome P450 3A expression and activity in the human small intestine. Clin Pharmacol Ther 2004;76:391
12. Rowland-Yeo, Rostami-Hodjegan A, Tucker GT. Abundance of cytochrome P450 in human liver: a meta-analysis. Br J Clin Pharmacol 2004;57:687-8
13. Kolars JC, Lown KS, Schmiedlin-Ren P, et al. CYP3A gene expression in human gut epithelium. Pharmacogenetics 1994;4:247-59
14. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 1997;27:161-70
15. Kivisto KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 2004;18:621-6
16. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003;42:59-98
17. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 2005;22:11-23
18. Endres CJ, Hsiao P, Chung FS, et al. The role of transporters in drug interactions. Eur J Pharm Sci 2006;27:501-17
19. Glaeser H, Bailey DG, Dresser GK, et al. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007;81:362-70
20. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005;78:260-77
21. Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007;8:787-802
22. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci 2006;27:425-46
23. Lapple F, von Richter O, Fromm MF, et al. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 2003;13:565-75
24. Thummel KE, Kunze KL, Shen DD. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 1997;27:99-127
25. Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84:265-9
26. Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 2003;20:1595-9
27. Thorn M, Finnstrom N, Lundgren S, et al. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 2005;60:54-60
28. Berggren S, Gall C, Wollnitz N, et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm 2007;4:252-7
29. Nakamura T, Sakaeda T, Ohmoto N, et al. Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab Dispos 2002;30:4-6
30. Cao X, Gibbs ST, Fang L, et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 2006;23:1675-86
31. Paine MF, Criss AB, Watkins PB, Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition. J Pharmacol Exp Ther 2005;312:1151-60
32. Galetin A, Houston JB, Intestinal and hepatic metabolic activity of five cytochrome P450 enzymes: impact on prediction of first-pass metabolism. J Pharmacol Exp Ther 2006;318:1220-9
33. Komura H, Iwaki M. Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 2007;97:1775-800
34. Obach RS, Zhang QY, Dunbar D, et al. Metabolic characterization of the major human small intestinal cytochrome p450s. Drug Metab Dispos 2001;29:347-52
35. van de Kerkhof EG, de Graaf IA, Groothuis GM. In vitro methods to study intestinal drug metabolism. Curr Drug Metab 2007;8:658-75
36. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91
37. Lin YS, Dowling AL, Quigley SD, et al. Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. Mol Pharmacol 2002;62:162-72
38. Einolf HJ. Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 2007;37:1257-94
39. Galetin A, Ito K, Hallifax D, et al. CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 2005;314:180-90
40. Galetin A, Burt H, Gibbons L, et al. Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 2006;34:166-75
41. Obach RS, Walsky RL, Venkatakrishnan K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 2007;35:246-55
42. Obach RS, Walsky RL, Venkatakrishnan K, et al. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006;316:336-48
43. Youdim KA, Zayed D, Dickins M, et al. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br J Clin Pharmacol 2008;65:680-92.
44. Houston JB, Galetin A. Modelling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 2005;433:351-60
45. Tang W, Stearns RA. Heterotropic cooperativity of cytochrome P450 3A4 and potential drug-drug interactions. Curr Drug Metab 2001;2:185-98
46. Brown HS, Ito K, Galetin A, et al. Prediction of in vivo drug-drug interactions from in vitro data: impact of incorporating parallel pathways of drug elimination and inhibitor absorption rate constant. Br J Clin Pharmacol 2005;60:508-18
47. Ito K, Hallifax D, Obach RS, et al. Impact of parallel pathways of drug elimination and multiple cytochrome P450 involvement on drug-drug interactions: CYP2D6 paradigm. Drug Metab Dispos 2005;33:837-44
48. Brown HS, Galetin A, Hallifax D, et al. Prediction of in vivo drug-drug interactions from in vitro data factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4. Clin Pharmacokinet 2006;45:1035-50
49. Hinton LK, Galetin A, Houston JB. Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharm Res 2008;25:1063-74
50. Rostami-Hodjegan A, Tucker G. 'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactions. Drug Discov Today Technol 2004;1:441
51. Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004;5:243-72
52. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001;40:159-68
53. Lundahl J, Regardh CG, Edgar B, et al. Effects of grapefruit juice ingestion - pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol 1997;52:139-45
54. Quinney SK, Haehner BD, Rhoades MB, et al. Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol 2008;65:98-109
55. Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997;62:41-9
56. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42:1141-60
57. Galetin A, Hinton LK, Burt H, et al. Maximal inhibition of intestinal first-pass metabolism as a pragmatic indicator of intestinal contribution to the drug-drug interactions for CYP3A4 cleared drugs. Curr Drug Metab 2007;8:685-93
58. Hirota N, Ito K, Iwatsubo T, et al. In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharm Drug Dispos 2001;22:53-71
59. Wang YH, Jones DR, Hall SD. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 2004;32:259-66
60. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815-32
61. Huang SM, Temple R, Throckmorton DC, et al. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007;81:298-304
62. Ito K, Brown HS, Houston JB. Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 2004;57:473-86
63. Tucker GT, Houston JB, Huang SM. Optimizing drug development strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Ther 2001;70:103-14
64. Chien JY, Lucksiri A, Ernest CS 2nd, et al. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole. Drug Metab Dispos 2006;34:1208-19
65. Garnet DY, Wacher VJ, Tomlanovich SJ, et al. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-9
66. Palkama VJ, Ahonen J, Neuvonen PJ, et al. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 1999;66:33-9
67. Saari TI, Laine K, Leino K, et al. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther 2006;79:362-70
68. Tsunoda SM, Velez RL, von Moltke LL, et al. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther 1999;66:461-71
69. Benet LZ, Cummins CL, Wu CY. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int J Pharm 2004;277:3-9
70. Galetin A. Intestinal first-pass metabolism: bridging the gap between in vitro and in vivo. Curr Drug Metab 2007;8:643-4
71. Chalasani N, Gorski JC, Patel NH, et al. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology 2001;34:1103-8
72. Rostami-Hodjegan A, Tucker GT. The effects of portal shunts on intestinal cytochrome P450 3A activity. Hepatology 2002;35:1549-50; author reply 1550-1
73. Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60:14-24
74. Thummel KE, O'Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491-502
75. Hall SD, Thummel KE, Watkins PB, et al. Molecular and Physical Mechanisms of First-Pass Extraction. Drug Metab Dispos 1999;27:161-6
76. Yang J, Jamei M, Yeo KR, et al. Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos 2007;35:501-2
77. Kato M, Chiba K, Hisaka A, et al. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein-quantitative analysis based on information from the literature. Drug Metab Pharmacokinet 2003;18:365-72
78. Bengtsson-Hasselgren B, Ronn O, Blychert LO, et al. Acute effects of felodipine and nifedipine on hepatic and forearm blood flow in healthy men. Eur J Clin Pharmacol 1990;38:529-33
79. Bailey DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998;46:101-10
80. Fuhr U. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf 1998;18:251-72
81. Kirby BJ, Unadkat JD. Grapefruit juice, a glass full of drug interactions? Clin Pharmacol Ther 2007;81:631-3
82. Saito M, Hirata-Koizumi M, Matsumoto M, et al. Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus an recent studies. Drug Saf 2005;28:677-94
83. Yang J, Jamei M, Yeo KR et al. Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 2007;8:676-84
84. Lundahl J, Regardh CG, Edgar B, et al. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol 1995;49:61-7
85. Honda Y, Ushigome F, Koyabu N, et al. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br J Pharmacol 2004;143:856-64
86. Becquemont L, Verstuyft C, Kerb R, et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001;70:311-6
87. Parker RB, Yates CR, Soberman JE, et al. Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy 2003;23:979-87
88. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. Clin Pharmacol Ther 2003;74:121-9
89. Lown KS, Bailey DG, Fantana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-53
90. Ito K, Kusuhara H, Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - theoretical approach. Pharm Res 1999;16:225-31
91. Pang KS. Modeling of intestinal drug absorption: roles of transporters and metabolic enzymes (for the Gillette Review Series). Drug Metab Dispos 2003;31:1507-19
92. Tam D, Tirona RG, Pang KS. Segmental intestinal transporters and metabolic enzymes on intestinal drug absorption. Drug Metab Dispos 2003;31:373-83
93. Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999;186:119-25
94. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001;50(Suppl 1):S41-67
95. Dokoumetzidis A, Kalantzi L, Fotaki N. Predictive models for oral drug absorption: from in silico methods to integrated dynamical models. Expert Opin Drug Metab Toxicol 2007;3:491-505
96. Rowland M, Benet LZ, Graham GG. Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1973;1:123-36 Defines concepts of clearance.
97. Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18:377-90
98. Lin JH, Chiba M, Baillie TA. In vivo assessment of intestinal drug metabolism. Drug Metab Dispos 1997;25:1107-9
99. Gorski JC, Jones DR, Haehner-Daniels BD, et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998;64:133-43
100. Lee JI, Chaves-Gnecco D, Amico JA, et al. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 2002;72:718-28
101. Masica AL, Mayo G, Wilkinson GR. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin Pharmacol Ther 2004;76:341-9
102. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305
103. Tateishi T, Watanabe M, Nakura H, et al. CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin Pharmacol Ther 2001;69:333-9
104. Wang Z, Gorski JC, Hamman MA, et al. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001;70:317-26
105. Farkas D, Oleson LE, Zhao Y, et al. Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice. J Clin Pharmacol 2007;47:286-94
106. Kharasch ED, Walker A, Hoffer C, et al. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis. Clin Pharmacol Ther 2004;76:452-66
107. Kupferschmidt HH, Ha HR, Ziegler WH, et al. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995;58:20-8
108. Kharasch ED, Walker A, Isoherranen N, et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther 2007;82:410-26
109. Kharasch ED, Hoffer C, Whittington D, et al. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 2004;76:250-69
110. Olkkola KT, Ahonen J, Neuvonen PJ. The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg 1996;82:511-6
111. Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther 1995;57:485-91
112. Gupta SK, Bakran A, Johnson RW, et al. Cyclosporin-erythromycin interaction in renal transplant patients. Br J Clin Pharmacol 1989;27:475-81
113. Hebert MF, Roberts JP, Prueksaritanont T, et al. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-7
114. Ku YM, Min DI, Flanigan M. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter? J Clin Pharmacol 1998;38:959-65
115. Lee M, Min DI, Ku YM, et al. Effect of grapefruit juice on pharmacokinetics of microemulsion cyclosporine in African American subjects compared with Caucasian subjects: does ethnic difference matter? J Clin Pharmacol 2001;41:317-23
116. Blychert E, Edgar B, Elmfeldt D, et al. A population study of the pharmacokinetics of felodipine. Br J Clin Pharmacol 1991;31:15-24
117. Holtbecker N, Fromm MF, Kroemer HK, et al. The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. Drug Metab Dispos 1996;24:1121-3
118. Damkier P, Hansen LL, Brosen K, Effect of fluvoxamine on the pharmacokinetics of quinidine. Eur J Clin Pharmacol 1999;55:451-6
119. Takanaga H, Ohnishi A, Murakami H, et al. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther 2000;67:201-14
120. Kupferschmidt HH, Fattinger KE, Ha HR, et al. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 1998;45:355-9
121. Skinner MH, Blaschke TF. Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet 1995;28:115-25
122. Skinner MH, Hsieh M, Torseth J, et al. Pharmacokinetics of rifabutin. Antimicrob Agents Chemother 1989;33:1237-41
123. Muirhead GJ, Rance DJ, Walker DK, et al. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. Br J Clin Pharmacol 2002;53(Suppl 1):13S-20S
124. Nichols DJ, Muirhead GJ, Harness JA. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 2002;53(Suppl 1):5S-12S
125. Abel S, Russell D, Whitlock LA, et al. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol 2008;65(Suppl 1):60-7
126. Greenblatt DJ, Friedman H, Burstein ES, et al. Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther 1987;42:193-200
127. Patat A, Trocherie S, Thebault JJ, et al. EEG profile of intravenous zolpidem in healthy volunteers. Psychopharmacology (Berl) 1994;114:138-46
128. Fromm MF, Busse D, Kroemer HK, et al. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996;24:796-801